Skip to main content
Top
Published in: Journal of Clinical Immunology 4/2019

01-05-2019 | Letter to Editor

Fifteen Years of the J Project

Authors: László Maródi, the J Project study group

Published in: Journal of Clinical Immunology | Issue 4/2019

Login to get access

Excerpt

Over the past 15 years, remarkable progress has been made of clinical care, laboratory diagnosis, and in particular, genetics in the field of primary immunodeficiency diseases (PIDs) [1]. This progress resulted mostly from a better understanding of the relationship between genotype and phenotype variability in patients with “normal” immunity and in those with increased susceptibility to infection, inflammatory and autoimmune disorders, allergy, and cancer [2]. The wondrous unraveling of the human genome sequence by virtue of the human genome project from 1991 to 2004, and later on by other international collaborative projects like HapMap, 1000 genome project, and ENCODE, has opened the way to the rapid development of the field [3]. Introduction of new generation sequencing (NGS), whole genome sequencing (WGS), and whole exome sequencing (WES) in 2010 revolutionized the diagnosis and research of PIDs leading to the discovery of hundreds of novel inborn errors of immunity [4]. Progress in basic sciences usually precipitates an increased activity of professional education and emerging of new programs like the J Project ambitious physician education and clinical research collaboration platform focusing primarily on Eastern and Central Europe (ECE) [5]. …
Literature
1.
go back to reference Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. Allergy Clin Immunol. 2013;131:314–23.CrossRef Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. Allergy Clin Immunol. 2013;131:314–23.CrossRef
2.
go back to reference Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38:96–128.CrossRefPubMed Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38:96–128.CrossRefPubMed
3.
go back to reference Antonarakis SE. Human genome sequence and variation. In: Speicher MR, Antonarakis SE, Motulsky AG, editors. Vogel and Motulsky’s human genetics: Springer; 2010. p. 31–53. Antonarakis SE. Human genome sequence and variation. In: Speicher MR, Antonarakis SE, Motulsky AG, editors. Vogel and Motulsky’s human genetics: Springer; 2010. p. 31–53.
4.
go back to reference Meyts I, Bosch B, Bolze A, Boisson B, Itan Y, Belkadi A, et al. Exome and genome sequencing for inborn errors of immunity. J Allergy Clin Immunol. 2016;138:957–69.CrossRefPubMedPubMedCentral Meyts I, Bosch B, Bolze A, Boisson B, Itan Y, Belkadi A, et al. Exome and genome sequencing for inborn errors of immunity. J Allergy Clin Immunol. 2016;138:957–69.CrossRefPubMedPubMedCentral
5.
go back to reference Maródi L, Casanova JL. Primary immunodeficiency diseases: the J Project. Lancet. 2009;373:2179–81.CrossRefPubMed Maródi L, Casanova JL. Primary immunodeficiency diseases: the J Project. Lancet. 2009;373:2179–81.CrossRefPubMed
6.
go back to reference Maródi L, The J Project Study Group. The creation and progress of the J Project in Eastern and Central Europe. Ann N Y Acad Sci. 2011;1238:65–73.CrossRefPubMed Maródi L, The J Project Study Group. The creation and progress of the J Project in Eastern and Central Europe. Ann N Y Acad Sci. 2011;1238:65–73.CrossRefPubMed
7.
go back to reference Horváth Z, Rezaei N, Reisli I, Tuzankina I, Otarbayev N, Popandopulo P, et al. The spread of the J Project. J Clin Immunol. 2013;33:1037–42.CrossRefPubMed Horváth Z, Rezaei N, Reisli I, Tuzankina I, Otarbayev N, Popandopulo P, et al. The spread of the J Project. J Clin Immunol. 2013;33:1037–42.CrossRefPubMed
8.
go back to reference Erdős M, Uzvölgyi E, Nemes Z, Török O, Rákóczi E, Went-Sümegi N, et al. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat. 2005;25:506.CrossRefPubMed Erdős M, Uzvölgyi E, Nemes Z, Török O, Rákóczi E, Went-Sümegi N, et al. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat. 2005;25:506.CrossRefPubMed
9.
go back to reference Soltész B, Tóth B, Shabashova N, Bondarenko A, Okada S, Cypowyj S, et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet. 2013;50:567–78.CrossRefPubMedPubMedCentral Soltész B, Tóth B, Shabashova N, Bondarenko A, Okada S, Cypowyj S, et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet. 2013;50:567–78.CrossRefPubMedPubMedCentral
Metadata
Title
Fifteen Years of the J Project
Authors
László Maródi
the J Project study group
Publication date
01-05-2019
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 4/2019
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-019-00633-4

Other articles of this Issue 4/2019

Journal of Clinical Immunology 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine